Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

iBio (IBIO) EBT Margin (2016 - 2025)

Historic EBT Margin for iBio (IBIO) over the last 17 years, with Q3 2025 value amounting to 5720.0%.

  • iBio's EBT Margin changed N/A to 5720.0% in Q3 2025 from the same period last year, while for Dec 2025 it was 8245.67%, marking a year-over-year decrease of 41832700.0%. This contributed to the annual value of 4594.25% for FY2025, which is 27137500.0% up from last year.
  • Latest data reveals that iBio reported EBT Margin of 5720.0% as of Q3 2025.
  • iBio's 5-year EBT Margin high stood at 374.89% for Q1 2022, and its period low was 10148.0% during Q3 2023.
  • Over the past 5 years, iBio's median EBT Margin value was 2182.0% (recorded in 2024), while the average stood at 3646.81%.
  • Over the last 5 years, iBio's EBT Margin had its largest YoY gain of 38691300bps in 2021, and its largest YoY loss of -50648200bps in 2021.
  • Quarter analysis of 5 years shows iBio's EBT Margin stood at 6902.38% in 2021, then surged by 95bps to 374.89% in 2022, then plummeted by -2607bps to 10148.0% in 2023, then surged by 78bps to 2182.0% in 2024, then tumbled by -162bps to 5720.0% in 2025.
  • Its EBT Margin stands at 5720.0% for Q3 2025, versus 2581.5% for Q2 2025 and 2182.0% for Q4 2024.